Engineered 'Super' immune cells target stubborn lymphoma in patients out of options
NCT ID NCT07283679
Summary
This study is testing a new combination treatment for adults with B-cell non-Hodgkin lymphoma that has come back or stopped responding to other therapies. It combines specially modified natural killer (NK) immune cells from donated umbilical cord blood with two antibody drugs (epcoritamab and tafasitamab). The main goals are to find a safe dose and see if this approach can help control the cancer in patients who have already tried multiple treatments, including CAR-T therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.